Cynata Therapeutics Limited (CYP.AX)
AUD 0.2
(5.41%)
AUD 0.2
(5.41%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 2.31 Million AUD | 39.98% |
| 2023 | 1.65 Million AUD | -78.71% |
| 2022 | 7.77 Million AUD | 402.6% |
| 2021 | 1.54 Million AUD | -77.95% |
| 2020 | 7.01 Million AUD | 435.83% |
| 2019 | 1.3 Million AUD | -4.84% |
| 2018 | 1.37 Million AUD | -21.37% |
| 2017 | 1.74 Million AUD | 59.03% |
| 2016 | 1.09 Million AUD | 285.08% |
| 2015 | 285.58 Thousand AUD | 1039.69% |
| 2014 | 25.05 Thousand AUD | -26.22% |
| 2013 | 33.96 Thousand AUD | -79.09% |
| 2012 | 162.45 Thousand AUD | -27.13% |
| 2011 | 222.93 Thousand AUD | 95.77% |
| 2010 | 113.87 Thousand AUD | 0.0% |
| 2009 | - AUD | -100.0% |
| 2008 | 350.56 Thousand AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.54 Million AUD | 0.0% |
| 2024 FY | - AUD | -100.0% |
| 2024 Q4 | -230.06 Thousand AUD | 0.0% |
| 2023 Q2 | 1.8 Million AUD | 0.0% |
| 2023 Q4 | -146.69 Thousand AUD | 0.0% |
| 2023 FY | 1.65 Million AUD | -78.71% |
| 2022 Q2 | 6.97 Million AUD | 0.0% |
| 2022 Q4 | 799.55 Thousand AUD | 0.0% |
| 2022 FY | 7.77 Million AUD | 402.6% |
| 2021 Q2 | 27.49 Thousand AUD | 0.0% |
| 2021 FY | 1.54 Million AUD | -77.95% |
| 2021 Q4 | 1.51 Million AUD | 0.0% |
| 2020 Q2 | 4.44 Million AUD | 0.0% |
| 2020 FY | 7.01 Million AUD | 435.83% |
| 2020 Q4 | 2.56 Million AUD | 0.0% |
| 2019 Q2 | 1.3 Million AUD | 0.0% |
| 2019 FY | 1.3 Million AUD | -4.84% |
| 2019 Q4 | -250.00 AUD | 0.0% |
| 2018 Q4 | -77.14 Thousand AUD | 0.0% |
| 2018 FY | 1.37 Million AUD | -21.37% |
| 2018 Q2 | 1.45 Million AUD | 0.0% |
| 2017 Q4 | -25.39 Thousand AUD | 0.0% |
| 2017 Q2 | 1.77 Million AUD | 0.0% |
| 2017 FY | 1.74 Million AUD | 59.03% |
| 2016 Q2 | 1.01 Million AUD | 0.0% |
| 2016 Q4 | 87.34 Thousand AUD | 0.0% |
| 2016 FY | 1.09 Million AUD | 285.08% |
| 2015 FY | 285.58 Thousand AUD | 1039.69% |
| 2015 Q4 | 242.23 Thousand AUD | 0.0% |
| 2015 Q2 | 43.35 Thousand AUD | 0.0% |
| 2014 FY | 25.05 Thousand AUD | -26.22% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 Q2 | 25.05 Thousand AUD | 0.0% |
| 2013 Q3 | 8491.00 AUD | -75.0% |
| 2013 Q2 | 33.96 Thousand AUD | -16.37% |
| 2013 Q1 | 40.61 Thousand AUD | 0.0% |
| 2013 FY | 33.96 Thousand AUD | -79.09% |
| 2013 Q4 | - AUD | -100.0% |
| 2012 Q4 | - AUD | -100.0% |
| 2012 Q2 | 40.61 Thousand AUD | -27.13% |
| 2012 Q1 | 55.73 Thousand AUD | 0.0% |
| 2012 FY | 162.45 Thousand AUD | -27.13% |
| 2012 Q3 | 40.61 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | -100.0% |
| 2011 Q3 | 55.73 Thousand AUD | 0.0% |
| 2011 Q2 | 55.73 Thousand AUD | 95.77% |
| 2011 Q1 | 28.46 Thousand AUD | 0.0% |
| 2011 FY | 222.93 Thousand AUD | 95.77% |
| 2010 Q3 | 28.46 Thousand AUD | 0.0% |
| 2010 Q2 | 28.46 Thousand AUD | 0.0% |
| 2010 Q4 | - AUD | -100.0% |
| 2010 Q1 | - AUD | 0.0% |
| 2010 FY | 113.87 Thousand AUD | 0.0% |
| 2009 Q2 | - AUD | -100.0% |
| 2009 FY | - AUD | -100.0% |
| 2009 Q3 | - AUD | 0.0% |
| 2009 Q1 | 87.64 Thousand AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | -100.0% |
| 2008 Q2 | 87.64 Thousand AUD | 0.0% |
| 2008 FY | 350.56 Thousand AUD | 0.0% |
| 2008 Q3 | 87.64 Thousand AUD | 0.0% |
| 2008 Q1 | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q2 | - AUD | 0.0% |
| 2007 Q3 | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AdAlta Limited | 1.73 Million AUD | -33.252% |
| Acrux Limited | 5.09 Million AUD | 54.515% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -284.773% |
| BTC Health Limited | 16.36 Thousand AUD | -14054.297% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 68.949% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 79.876% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 97.374% |
| Biome Australia Limited | 13 Million AUD | 82.2% |
| Hexima Limited | - AUD | -Infinity% |
| Immutep Limited | 3.5 Million AUD | 33.947% |
| Memphasys Limited | 60 Thousand AUD | -3759.405% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 99.002% |
| Noxopharm Limited | 2.4 Million AUD | 3.526% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 37.623% |
| Race Oncology Limited | 4 Million AUD | 42.159% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -673.872% |
| Starpharma Holdings Limited | 8.28 Million AUD | 72.064% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -1421.048% |
| Biotron Limited | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 4.01 Million AUD | 42.387% |
| CSL Limited | 22.41 Billion AUD | 99.99% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 96.515% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -12539.973% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -2338.751% |
| Patrys Limited | 1.39 Million AUD | -66.096% |
| Orthocell Limited | 5.31 Million AUD | 56.435% |
| Imugene Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | 22.05 Million AUD | 89.503% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -159.56% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -13521.429% |
| Nanollose Limited | 12.5 Thousand AUD | -18423.662% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -91.019% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 4.45 Million AUD | 47.995% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -85.018% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 99.534% |
| Dimerix Limited | 583.47 Thousand AUD | -296.869% |
| PharmAust Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | -402.967% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -3419.214% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -388.995% |
| Actinogen Medical Limited | 9.93 Million AUD | 76.684% |
| Immuron Limited | 4.9 Million AUD | 52.77% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 10.866% |